Source:http://linkedlifedata.com/resource/umls/id/C0034738
MSH: An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex.,PDQ: A bis-dioxopiperazine and a derivative of the chelating agent EDTA with antineoplastic activity. Razoxane inhibits the enzyme topoisomerase II without inducing DNA strand breaks, thereby inhibiting DNA synthesis and inducing cytotoxicity. Although its mechanism is unknown, this agent exhibits anti-angiogenic activity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39480&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39480&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C801" NCI Thesaurus),NCI: An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic ac